Abstract
Background
Breast cancer is the most frequent type of tumor in women. The main cause of breast cancer remains unknown. Extensive studies have shown that endogenous steroid hormones, especially estrogens, are important in the development and the progression of breast cancer, and the carcinogenesis of estrogens is related to their major oxidative metabolites, 16α-hydroxyestrogens and 4-hydroxyestrogens. CYP3A plays a major role in the 4- and 16α-hydroxylation of estrogens. Furthermore, CYP3A is present in human mammary epithelial cells and expressed higher and more frequently in malignant breast cells than in the adjacent normal breast tissue. Hence, it will be significant to perform more work to determine the association between CYP3A activity and breast cancer susceptibility.
Aims
To evaluate the relationship of CYP3A activity to breast cancer susceptibility in Chinese Han women using the plasma 1-hydroxymidazolam (1-OHMDZ) to midazolam (MDZ) ratio as the marker of CYP3A activity.
Methods
One hundred and twenty-nine Chinese Han female breast tumor patients and 121 healthy unrelated female volunteers were enrolled in the current study. After an overnight fast, each subject was administered a single oral dose (7.5 mg) of midazolam. Blood samples (5 ml) were drawn at 1 h after the drug administration. The concentration of parent MDZ and its major metabolite 1-OH-MDZ was measured in all the plasma samples using high-performance liquid chromatography.
Results
Complete chromatographic data on plasma ratios of 1-OHMDZ to MDZ for 103 cases of breast cancer and 114 controls were available. The plasma concentration ratios of 1-OHMDZ to MDZ were 0.4520±0.2318 and 0.3298±0.1610 for the malignant cases and the controls, respectively. A higher CYP3A activity was found in the breast cancer cases than in the controls (P<0.001), and the CYP3A activity of patients with lymph-node metastasis was higher than that of patients without lymph-node metastasis (P=0.028). CYP3A activity in estrogen receptor or progesterone receptor positive cases was the same as in estrogen receptor or progesterone receptor negative cases (P=0.124, 0.175).
Conclusions
Our results indicate that high CYP3A activity may contribute to breast cancer disease genesis and may promote breast cancer to lymph-node metastasis.
Similar content being viewed by others
References
Lacey JV Jr, Devesa SS, Brinton LA (2002) Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 39:82–88
Key TJ (1999) Serum oestradiol and breast cancer risk. Endocr Relat Cancer 6:175–180
Colditz GA (1998) Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90:814–823
Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133–140
Key TJ, Pike MC (1988) The role of oestrogens and progestrogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24:29–43
Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73
Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1–27
Liehr JG (1997) Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 6:3–10
Cavalieri EL, Stack DE, Devanesan PD, et al (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 94:10937–10942
Huang ZQ, Guengerich FP, Kaminsky LS (1998) 16α-hydroxylation of estrone by human cytochrome P450 3A4/5. Carcinogenesis 19:867–872
Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV (1997) Role of human hepatic cytochrome CYP1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207–214
Huang ZQ, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24:899–905
Galant C, Gala JL, Van Den Berge V, Berliere M, Haumont E, Horsmans Y (2001) Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors. Pharmacol Toxicol 88:142–146
Zheng W, Jin F, Dunning LA, et al (2001) Epidemiological study of urinary 6ß-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10:237–242
Horita K, Yamaguchi A, Hirose K, et al (2001) Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 45:73–84
Paulussen A, Lavrijsen K,Bohets H, et al (2000) Two linked mutatuins in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10:415–424
Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216
Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH (2001) Single plasma sampling to predict oral clearance of the CYP3A probe midazolam. Acta Pharmacologica Sinica 22:634–638
Watkins PB (1995) Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 22:994–995
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485–505
Schmucker DL, Woodhouse KW, Wang RK, et al (1990) Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48:365–374
Kinirons MT, O'Shea D, Downing TE, et al (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54:621–629
Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275–283
Hunt CM, Watkins PB, Saenger P, et al (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51:18–23
Hashimoto H, Toide K, Kitamura R, et al (1993) Gene structure of CYP3A4, and adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585–595
Abrams JS (2001) Adjuvant therapy for breast cancer—results from the USA consensus conference. Breast Cancer 8:298–304
Shimada T, Guengerich FP (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc Natl Acad Sci U S A 86:462–465
Lown KS, Thummel KE, Benedict PE, et al (1995) The erythromycin breast test predicts the clearance of midazolam. Clin Pharmacol Ther 57:16–24
Hsieh KP, Lin YY, Cheng CL, et al (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268–273
Gorski JC, Hall SD, Jones DR, Vanden-branden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643–1653
Sheweita SA (2000) Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 1:107–132
Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S (2002) Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129–132
Acknowledgements
We thank the staff at the Department of Surgery in the Tumor Hospital of Hunan Province for the collection of all breast cancer samples. This project was supported by China Medical Board grants 99–697 and 01–755, and National Natural Science Foundation of China grant F30130210.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, P., Zhu, B., Wang, LS. et al. Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. Eur J Clin Pharmacol 59, 471–476 (2003). https://doi.org/10.1007/s00228-003-0649-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0649-4